CA2716426A1 - Inactivation d'un pathogene dans un echantillon par traitement a la formaline et a la lumiere ultraviolette - Google Patents
Inactivation d'un pathogene dans un echantillon par traitement a la formaline et a la lumiere ultraviolette Download PDFInfo
- Publication number
- CA2716426A1 CA2716426A1 CA2716426A CA2716426A CA2716426A1 CA 2716426 A1 CA2716426 A1 CA 2716426A1 CA 2716426 A CA2716426 A CA 2716426A CA 2716426 A CA2716426 A CA 2716426A CA 2716426 A1 CA2716426 A1 CA 2716426A1
- Authority
- CA
- Canada
- Prior art keywords
- sample
- virus
- formalin
- inactivation
- light
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 title claims abstract description 154
- 230000002779 inactivation Effects 0.000 title claims description 68
- 244000052769 pathogen Species 0.000 title description 13
- 230000001717 pathogenic effect Effects 0.000 title description 10
- 241000700605 Viruses Species 0.000 claims abstract description 122
- 238000000034 method Methods 0.000 claims abstract description 39
- 230000000415 inactivating effect Effects 0.000 claims abstract description 14
- 229960005486 vaccine Drugs 0.000 claims description 28
- 238000004113 cell culture Methods 0.000 claims description 20
- 230000009467 reduction Effects 0.000 claims description 13
- 238000000746 purification Methods 0.000 claims description 7
- 229940127554 medical product Drugs 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000013060 biological fluid Substances 0.000 claims description 3
- 241001493065 dsRNA viruses Species 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 33
- 101710154606 Hemagglutinin Proteins 0.000 description 23
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 23
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 23
- 101710176177 Protein A56 Proteins 0.000 description 23
- 239000000185 hemagglutinin Substances 0.000 description 23
- 238000011076 safety test Methods 0.000 description 21
- 238000003306 harvesting Methods 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 18
- 210000003501 vero cell Anatomy 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 230000003612 virological effect Effects 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 239000000427 antigen Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- 230000005847 immunogenicity Effects 0.000 description 12
- 230000005855 radiation Effects 0.000 description 11
- 235000013601 eggs Nutrition 0.000 description 10
- 206010022000 influenza Diseases 0.000 description 10
- 230000000120 cytopathologic effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000845082 Panama Species 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 7
- 241000700198 Cavia Species 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 238000011026 diafiltration Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- 241000711573 Coronaviridae Species 0.000 description 4
- 241000991587 Enterovirus C Species 0.000 description 4
- 241000710831 Flavivirus Species 0.000 description 4
- 208000000474 Poliomyelitis Diseases 0.000 description 4
- 241000710942 Ross River virus Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000035931 haemagglutination Effects 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 241000712891 Arenavirus Species 0.000 description 3
- 241000711950 Filoviridae Species 0.000 description 3
- 241000713112 Orthobunyavirus Species 0.000 description 3
- 241000709664 Picornaviridae Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 244000309457 enveloped RNA virus Species 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000007887 Alphavirus Infections Diseases 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000710954 Ross river virus (STRAIN T48) Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000011172 small scale experimental method Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57531004P | 2004-05-27 | 2004-05-27 | |
| US60/575,310 | 2004-05-27 | ||
| CA2567336A CA2567336C (fr) | 2004-05-27 | 2005-05-26 | Inactivation d'un pathogene dans un echantillon par traitement a la formaline et a la lumiere ultraviolette |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2567336A Division CA2567336C (fr) | 2004-05-27 | 2005-05-26 | Inactivation d'un pathogene dans un echantillon par traitement a la formaline et a la lumiere ultraviolette |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2716426A1 true CA2716426A1 (fr) | 2005-12-15 |
Family
ID=43064703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2716426A Abandoned CA2716426A1 (fr) | 2004-05-27 | 2005-05-26 | Inactivation d'un pathogene dans un echantillon par traitement a la formaline et a la lumiere ultraviolette |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2716426A1 (fr) |
-
2005
- 2005-05-26 CA CA2716426A patent/CA2716426A1/fr not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5675690B2 (ja) | ホルマリンおよびｕｖ光での処理によるサンプル中の病原体の不活化 | |
| KR101760844B1 (ko) | 바이러스성 백신의 제조 방법 | |
| AU764592B2 (en) | Methods and compositions for the selective modification of nucleic acids | |
| US8703467B2 (en) | Inactivation of a pathogen in a sample by a treatment with formalin and UV light | |
| CN105431171A (zh) | 用于使用电子射线来病毒灭活的方法 | |
| Gracheva et al. | Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light | |
| Vaidya et al. | Ultraviolet-C irradiation for inactivation of viruses in foetal bovine serum | |
| US6352695B1 (en) | Methods and compositions for the selective modification of nucleic acids | |
| CA2716426A1 (fr) | Inactivation d'un pathogene dans un echantillon par traitement a la formaline et a la lumiere ultraviolette | |
| KR20070030852A (ko) | 포르말린 및 ｕｖ광으로의 처리에 의한 샘플 중 병원균의불활성화 | |
| HK1105374B (en) | A method for inactivating a virus contained in a sample | |
| US20250177534A1 (en) | Thermostable uv inactivated vaccines and other biopharmaceuticals | |
| WO2014155297A2 (fr) | Systemes et procedes pour l'inactivation virale de compositions de vaccin par traitement par des glucides et un rayonnement | |
| Zarubaev et al. | Photodynamic inactivation of enveloped viruses by fullerene: study of efficacy and safety | |
| Mayerhofer et al. | UV irradiation for the manufacturing of viral vaccines: state-of-the-art and perspectives in modern vaccine processing | |
| Sofer | Part 4, culture media, biotechnology products, and vaccines | |
| Kamran Mousavi et al. | Pasteurization of IgM-enriched immunoglobulin | |
| HK1143328B (en) | Method for producing viral vaccines | |
| SE204939C1 (fr) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |
Effective date: 20130528 |